The Synairgen (LON:SNG) share price fell back to pre-Covid levels at one point on Monday following the disappointing phase III data for the SPRINTER trial for SNG001 use in hospitalised Covid-19 patients. The share price has recovered since then, but it has still lost four-fifths in one day. There is cash in the bank, but Synairgen’s fortunes need to be reassessed.
The headline data for the trial did not meet primary or secondary endpoints. finnCap believes that the disappointing resu...
You are unauthorized to view this page.